• Forest Laboratories Inc., of New York, said its Canadian subsidiary, Forest Laboratories Canada Inc., received a notice of compliance from Health Canada for Bystolic (nebivolol) tablets, a once-daily beta blocker for hypertension. The drug is expected to launch in Canada in the second quarter.

• Pfizer Inc., of New York, said the Committee for Medicinal Products for Human Use of the European Medicines Agency offered a positive opinion on the conditional marketing authorization of bosutinib in the European Union (EU) in chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia patients previously treated with one or more tyrosine kinase inhibitors and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. Pfizer expects a formal decision from the EU in the coming months.